Fig. 8

PERK inhibitor treatment significantly inhibits PERK signaling and consequently ameliorates DICD. a The learning curve of training period during 6 blocks in the Morris water maze test of mice after treating with GSK2356157 or FGF1, n = 8; b Representative swimming track of mice at block 1 and block 6 during training period; c-d Number of crossing over the original platform location and latency time to find the platform of mice in probe trial (1 h and 24 h after training) after treating with GSK2356157 or FGF1, n = 8; e Representative swimming track of mice in probe trial (1 h and 24 h after training); (f) Western blotting and quantitative analysis of p-PERK, p-eIF2α, BDNF and p-CREB (S133) expressions in the hippocampus of mice after treatment with GSK2356157 or FGF1, n = 3; g Western blotting and quantitative analysis of synaptic function related protein expressions (PSD95, synaptophysin and synapsin-1) in the hippocampus of mice after treatment with GSK2356157 or FGF1, n = 3. GSK: GSK2356157. *p < 0.05 vs. the other two groups